Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

Cancer Immunology, Immunotherapy

Volumn 66, Issue 5, 2017, Pages 581-592

  Bergqvist, Viktoria ^a   Hertervig, Erik ^a,c   Gedeon, Peter ^a   Kopljar, Marija ^a   Griph, Håkan ^a   Kinhult, Sara ^a,c   Carneiro, Ana ^a,c   Marsal, Jan ^a,b,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Immune checkpoint inhibitor induced enterocolitis; Ipilimumab; Lung cancer; Melanoma; Nivolumab; Vedolizumab treatment against irAEs

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN; CARBOPLATIN; CORTICOSTEROID; DACARBAZINE; DOCETAXEL; GEMCITABINE; IPILIMUMAB; METHYLPREDNISOLONE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; TEMOZOLOMIDE; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE STUDY; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROCOLITIS; FECES LEVEL; FEMALE; HEMICOLECTOMY; HUMAN; MALE; MEDICAL HISTORY; METASTATIC MELANOMA; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; ULCERATIVE COLITIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; DRUG EFFECTS; LUNG NEOPLASMS; MELANOMA; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; ENTEROCOLITIS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED;

EID: 85012893091     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1962-6     Document Type: Article

References (54)

1. Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106. doi:10.1097/COC.0000000000000239
2. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 112(19):6140–6145. doi:10.1073/pnas.1417320112
3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34. doi:10.1056/NEJMoa1504030
4. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697. doi:10.1200/JCO.2012.41.6750
5. Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60. doi:10.1016/j.ctrv.2016.02.001
6. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, Investigators CA (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700–712. doi:10.1016/S1470-2045(14)70189-5
7. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522–530. doi:10.1016/S1470-2045(15)70122-1
8. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, investigators K- (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. doi:10.1056/NEJMoa1503093
9. Spain L, Larkin J (2016) Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy 8 (6):677–679. doi:10.2217/imt.16.6
10. Poullis A, Foster R, Mendall MA, Fagerhol MK (2003) Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 18(7):756–762
11. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103(1):162–169. doi:10.1111/j.1572-0241.2007.01556.x
12. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. doi:10.1093/jnci/dju124
13. Callahan MK, Wolchok JD, Allison JP (2010) Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37(5):473–484. doi:10.1053/j.seminoncol.2010.09.001
14. Gruver-Yates AL, Cidlowski JA (2013) Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells 2(2):202–223. doi:10.3390/cells2020202
15. Levin AD, Wildenberg ME, van den Brink GR (2016) Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 10(8):989–997. doi:10.1093/ecco-jcc/jjw053
16. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, Group GS (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721. doi:10.1056/NEJMoa1215739
17. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, Group GS (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710. doi:10.1056/NEJMoa1215734
18. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC (1993) Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74(1):185–195
19. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864–875. doi:10.1124/jpet.109.153973
20. Wyant T, Fedyk E, Abhyankar B (2016) An Overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 10(12):1437–1444. doi:10.1093/ecco-jcc/jjw092
21. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG (2016) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. doi:10.1136/gutjnl-2015-311079
22. Bryant RV, Sandborn WJ, Travis SP (2015) Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis 9(4):356–366. doi:10.1093/ecco-jcc/jjv033
23. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 102(4):803–813. doi:10.1111/j.1572-0241.2007.01126.x
24. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. (U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; 2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
25. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ (2013) Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145(5):987–995. doi:10.1053/j.gastro.2013.07.024
26. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60(4):505–512
27. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ (2015) The impact of clinical information on the assessment of endoscopic activity: characteristics of the ulcerative colitis endoscopic index of severity [UCEIS]. J Crohns Colitis 9(8):607–616. doi:10.1093/ecco-jcc/jjv077
28. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649–655
29. Hsieh AH, Ferman M, Brown MP, Andrews JM (2016) Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Rep 2016. doi:10.1136/bcr-2016-216641
30. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143 (2):390–399. doi:10.1053/j.gastro.2012.05.004
31. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904. doi:10.1136/ard.2010.149419
32. Raaschou P, Simard JF, Holmqvist M, Askling J, Group AS (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:f1939. doi:10.1136/bmj.f1939
33. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886–2895. doi:10.1002/art.22864
34. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–2285. doi:10.1001/jama.295.19.2275
35. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ (2009) Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol 104(10):2524–2533. doi:10.1038/ajg.2009.322
36. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134(4):929–936. doi:10.1053/j.gastro.2008.01.012
37. Del Castillo M, Romero FA, Arguello E, Kyi C, Postow MA, Redelman-Sidi G (2016) The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63(11):1490–1493. doi:10.1093/cid/ciw539
38. Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB (2010) Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3 + T cells. Dig Dis Sci 55(5):1396–1405. doi:10.1007/s10620-009-0839-8
39. Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA (2014) Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2:19. doi:10.1186/2051-1426-2-19
40. Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C (2015) Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology 4(10):e1040218. doi:10.1080/2162402X.2015.1040218
41. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24(15):2283–2289. doi:10.1200/JCO.2005.04.5716
42. Pages C, Gornet JM, Monsel G, Allez M, Bertheau P, Bagot M, Lebbe C, Viguier M (2013) Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 23(3):227–230. doi:10.1097/CMR.0b013e32835fb524
43. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33(28):3193–3198. doi:10.1200/JCO.2015.60.8448
44. Arriola E, Wheater M, Karydis I, Thomas G, Ottensmeier C (2015) Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 21(24):5642–5643. doi:10.1158/1078-0432.CCR-15-2471
45. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053. doi:10.1200/JCO.2005.06.205
46. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825–830. doi:10.1097/CJI.0b013e318156e47e
47. Yousaf N, Davidson M, Goode E, Thomas C, Hung R, Gore M, Larkin J (2015) The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Res 25(3):259–264. doi:10.1097/CMR.0000000000000158
48. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13(22):6681–6688. doi:10.1158/1078-0432.CCR-07-0187
49. Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19(14):3977–3986. doi:10.1158/1078-0432.CCR-12-3243
50. De Felice KM, Gupta A, Rakshit S, Khanna S, Kottschade LA, Finnes HD, Papadakis KA, Loftus EV Jr, Raffals LE, Markovic SN (2015) Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 25(4):321–327. doi:10.1097/CMR.0000000000000165
51. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18(7):2039–2047. doi:10.1158/1078-0432.CCR-11-1823
52. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O’Day SJ, Lebbe C (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164. doi:10.1016/S1470-2045(09)70334-1
53. Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK (2016) Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 14(6):836–842. doi:10.1016/j.cgh.2015.12.028
54. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240. doi:10.1001/jamaoncol.2015.4368